Predicting who benefits from pre-surgery immunotherapy for non-small cell lung cancer using scans, immune, and genetic markers
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer
Looks at whether combining CT scans with immune and genetic tumor markers can help doctors pick which patients with operable non-small cell lung cancer will benefit from immunotherapy before surgery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11180515 on NIH RePORTER |
What this research studies
If you join, doctors will combine CT imaging with detailed analyses of your tumor’s immune cells and genetic features to map different “habitats” within the tumor. They will collect tumor tissue (and possibly blood) before and after immunotherapy given prior to surgery and compare those lab results with the imaging maps. The team will search for patterns that match a strong tumor response to the pre-surgery immunotherapy. Those patterns would be used to help predict who is most likely to have a major pathologic response.
Who could benefit from this research
Good fit: People with resectable (operable) non-small cell lung cancer who are being considered for immunotherapy before surgery would be the ideal candidates.
Not a fit: Patients with metastatic or unresectable lung cancer, small cell lung cancer, or those ineligible for immunotherapy or surgical treatment are unlikely to benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could help select patients who are likely to benefit from immunotherapy before surgery and spare others from unnecessary side effects.
How similar studies have performed: Previous neoadjuvant immunotherapy trials in resectable NSCLC have shown promise, but using combined imaging and immune/genomic 'habitat' markers to predict response is a newer approach that is still being tested.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Wu, Jia — University of Tx Md Anderson Can Ctr
- Study coordinator: Wu, Jia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.